Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biodexa Pharmaceuticals plc - American Depositary Shares (NQ:BDRX)

2.440 -0.250 (-9.29%)
Delayed Quote Updated: 11:00 AM EST, Nov 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Biodexa Pharmaceuticals plc - American Depositary Shares

News headline image
The Longview: Fireside Chat with Biodexa CEO Stephen Stamp
Today's interview with Stephen Stamp, CEO of Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) is about the Company's lead program, eRapa in Familial Adenomatous Polyposis (FAP), a genetic disease of the lower... 
From Biodexa Pharmaceuticals PLC
Via ACCESS Newswire
News headline image
Microcap Madness: DOSE, GV, GPUS, ADMQ, BDRX, AMLM Finals to Watch
Via AB Newswire
Topics Artificial Intelligence Intellectual Property
News headline image
Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer
Via ACCESS Newswire
News headline image
Surging Stocks: AMCI, BDRX, SURG, VMAR, TOON More Stocks Inside
Via AB Newswire
News headline image
Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer
Via ACCESSWIRE
News headline image
Biodexa Looks To Prevent Or Delay The Worst Outcomes For Adolescents And Young Adults With Devastating Precancerous Condition
Via ACCESSWIRE
News headline image
Biodexa's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers
Via ACCESSWIRE
News headline image
Myseum (NASDAQ: MYSE) Realizes $6.8M in Asset Sale – Watch AMCI, ARTV, QIPT, SURG Today!
Via AB Newswire
News headline image
ENDRA Life Sciences (NASDAQ: NDRA) Advances TAEUS® Liver Imaging, Strengthens Capital Efficiency; WVE, TWG, BDRX, FULC Also Active
Via AB Newswire
News headline image
Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled
Via ACCESS Newswire
News headline image
How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market
Via ACCESS Newswire
News headline image
Biodexa Takes Aim At Type 1 Diabetes With Innovative Drug Candidate Tolimidone
Via ACCESSWIRE
News headline image
Biodexa Pharmaceuticals PLC Announces Exercise of Pre-Funded Warrants & Issue of Equity
Via ACCESSWIRE
News headline image
Biodexa Pharmaceuticals PLC Announces Exercise of Pre-Funded Warrants & Issue of Equity
Via ACCESSWIRE
News headline image
Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study
Via ACCESS Newswire
News headline image
With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter
Via ACCESS Newswire
News headline image
Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status
Via ACCESS Newswire
News headline image
Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic
Via ACCESSWIRE
News headline image
Biodexa Pharmaceuticals PLC Announces Exercise of Pre-Funded Warrants & Issue of Equity
Via ACCESSWIRE
News headline image
Biodexa Pharmaceuticals PLC Announces Exercise of Pre-Funded Warrants & Issue of Equity
Via ACCESSWIRE
News headline image
Biodexa Pharmaceuticals PLC Announces Exercise of Pre-Funded Warrants & Issue of Equity
Via ACCESSWIRE
News headline image
Biodexa Pharmaceuticals PLC Announces Issue of Pre-Funded Warrants
Via ACCESSWIRE
News headline image
BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
Biodexa Announces Additional Positive Results Of Phase 2 Trial Of eRapa in Treatment Of Precancerous Polyps in the GI Tract - Now 12-Month Data
Via ACCESSWIRE
News headline image
Biodexa Pharmaceuticals PLC Announces Exercise of Warrants and Issue of Equity
Via ACCESSWIRE
News headline image
Biodexa Pharmaceuticals PLC Announces Exercise of Warrants and Issue of Equity
Via ACCESSWIRE
News headline image
Biodexa Pharmaceuticals PLC Announces Exercise of Warrants and Issue of Equity
Via ACCESSWIRE
News headline image
Promising Phase 2 Results For Biodexa's eRapa(TM) Indicates Hope for FAP Patients Who Otherwise Have a 100% Lifetime Risk of Colorectal Cancer
Via ACCESSWIRE
Biotech Market Update: Global Pharmaceuticals Market Expected to Reach $1.5 Trillion by Year’s End
EQNX::TICKER_START (NYSE:PTN),(NASDAQ:CRDF),(NASDAQ:BDRX),(NASDAQ:DRUG),(NYSE:LLY) EQNX::TICKER_END 
Via FinancialNewsMedia
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.